Omid Farokhzad is the Chair and Chief Executive Officer for Seer. Previously, he was Professor at Harvard Medical School and directed the Center for Nanomedicine at Brigham and Women’s Hospital. He has authored over 175 papers and is an inventor of over 200 issued and pending patents. Omid previously founded BIND Therapeutics (NASDAQ: BIND, acquired by Pfizer), Selecta Biosciences (NASDAQ: SELB), and Tarveda Therapeutics. He is a 2018 Fellow of the National Academy of Inventors. He is a recipient of the 2016 Ellis Island Medal of Honor and the 2014 Golden Door Award from the International Institute of New England, for his scientific, societal and economic contributions to America as an immigrant; the 2013 RUSNANOPRIZE, one of the largest international nanotechnology prizes for his work on nanomaterial surface modification; and the 2012 Ernst & Young New England Entrepreneur of the Year award. He received his M.D. and M.A. from Boston University and his M.B.A. from MIT Sloan School of Management.
David R. Horn is the Chief Financial Officer for Seer. Prior to joining Seer, Mr. Horn worked at Morgan Stanley for over 20 years, where he served as a Managing Director in the firm’s Global Healthcare Group within the Investment Banking Department. Mr. Horn was responsible for Morgan Stanley’s global Life Science Tools and Diagnostics practice and oversaw the Western Region Healthcare practice. In addition, Mr. Horn previously spent time working in the medical device and life science sectors where he served as Vice President of Business Development at RITA Medical Systems and, prior to that, in the same role at Chemdex Corporation. Mr. Horn holds a Bachelor of Arts from Princeton University and an MBA from the Stanford University Graduate School of Business.
Elona Kogan has served as our General Counsel and Secretary since November 2020. Prior to joining us, Ms. Kogan served as General Counsel and Secretary of Selecta Biosciences, Inc., a clinical-stage biotechnology company, from March 2019 to August 2020. From July 2016 to April 2017, Ms. Kogan served as General Counsel and Head of Government Relations at ARIAD Pharmaceuticals, Inc., a rare disease oncology company, where she was a key executive through the acquisition of the company by Takeda Pharmaceuticals Company Limited. Ms. Kogan led the legal and government affairs functions of Avanir Pharmaceuticals, Inc., a publicly traded pharmaceutical company, from May 2011 to August 2015, until its acquisition by Otsuka Pharmaceutical Co. Ltd. Prior roles included positions of increasing responsibility at King Pharmaceuticals, Inc., Bristol-Myers Squibb, and Bergen Brunswig Corporation. Ms. Kogan is also a member of the board of Cardax, Inc. and serves as the Chairperson of the Compensation Committee and a member of the Audit Committee. Ms. Kogan is a graduate of the SCALE program at Southwestern University School of Law. Ms. Kogan graduated cum laude from Columbia University, Barnard College, with a B.A. in economics.
Karen is Chief Marketing Officer at Seer. She was most recently Vice President, Global Marketing and Communications for Illumina Inc. overseeing all areas of communications, marketing, eCommerce and corporate citizenship over a 16 year period of rapid growth. During her tenure at Illumina, Karen also served as Chief of Staff to the CEO across two CEOs, established the Women’s Leadership Network, founded the Illumina Foundation and drove multiple cross-sector programs for the company. Prior to Illumina, she served in commercial leadership roles at Qiagen and Invitrogen, building from early stage success and profitability to growth at scale. Karen has received multiple awards in the community, including San Diego Business Journal Business Woman of the Year 2019. She is a member of the Dean’s Leadership Council for the Biological Sciences Division of UCSD. Karen holds a Bachelor’s in Biochemistry and Cell Biology from the University of California, San Diego.
Prior to joining Seer, Mr. Thomas led the go-to-market strategy for Singular Genomics’ next-generation benchtop sequencer, consumables, and service products. He has held numerous roles with escalating commercial responsibilities at Illumina including Vice President, Global Commercial Strategy and Enablement. Previously he served as Vice President and General Manager of Illumina Japan, and Senior Director, Sales for Europe, Middle East, and Africa. Before his tenure at Illumina, Scott held roles for Providence Health and Services, Roche, Abbott Laboratories and Sigma Alpha Epsilon. Scott holds a bachelor’s degree in Public Relations from the University of Idaho, a master’s degree in Healthcare administration from the University of Washington and completed the Advanced Management Program (AMP) at the IESE Business School, University of Navarra.
Marissa is our Chief People Officer. Prior to joining Seer, Marissa was Vice President of Human Resources of CareDx where she helped to grow the business from 70 million and 140 employees to over 190 million and 500 employees in a little over 3 years. Marissa brings over 20 years of human resources leadership experience to Seer, holding various HR roles with increasing responsibility in the biotech industry at companies such as Metabiota and DuPont Industrial Biosciences. Marissa holds Master’s degrees in HR Design and Psychology from Claremont Graduate University. In addition, she holds a Bachelor’s in Social Sciences from California Polytechnic State University, San Luis Obispo.
Serafim Batzoglou is Chief Data Officer at Seer. Prior to joining Seer, Serafim served as Chief Data Officer at Insitro, leading machine learning and data science in their approach to drug discovery. Prior to Insitro, he served as VP of Applied and Computational Biology at Illumina, leading research and technology development of AI and molecular assays for making genomic data more interpretable in human health. Serafim was a co-founder of DNAnexus Inc. in 2009. He spent 15 years at Stanford University as Professor of Computer Science and Biomedical Data Sciences, and as a member of the Stanford AI Lab (SAIL). He has received numerous awards and distinctions, including Top Young Technology Innovator in MIT Technology Review in 2003, the inaugural Innovator Award by the International Society for Computational Biology (ISCB) in 2016, and Fellow of the ISCB in 2020. Serafim has served on several scientific advisory boards including those of 23andMe, NextBio, DNAnexus, Eve Biomedical, Genapsys and Moleculo. Serafim holds a PhD in Computer Science from Massachusetts Institute of Technology.
Kenny is Chief Operations and Product Officer at Seer. Prior to Seer, Kenny was VP, Factory of the Future at Illumina. Kenny’s responsibilities included Global Manufacturing Strategy, Operational Excellence, Automation, Operations Technology, Data Analytics and Process Development, and Transfer for Consumables New Product Introduction. Prior to Illumina, Kenny was Vice President, Global Operations for the Genetic Sciences (GSD) and Clinical Next-Gen Sequencing (CSD) Divisions of Thermo Fisher Scientific, supporting annual revenue of $4B per year. Kenny also spent a number of years with increasing operational responsibility at Applied Biosystems and Life Technologies, both in the UK and the US, and had Operational responsibilities for the TaqMan, AmpliSeq, HID and Ion Torrent product lines. Kenny has a PhD in Bioorganic Chemistry from Aston University, with a focus on solid-phase oligonucleotide synthesis.
Marty is Senior Vice President of Development at Seer. Prior to Seer, Marty was at Talis Biomedical Corporation where he served most recently as Sr. VP, Operations and prior to that, Sr. VP Research & Development. Before joining Talis, he was Chief Operating Office at Gen9, a synthetic biology startup. Marty was at Affymetrix from 1993 to 2010 in roles of increasing responsibility, where he established and oversaw the company’s first wafer scale manufacturing facility, and also as Sr. VP R&D, where he had responsibility for the commercialization of numerous GeneChip® products ranging from new gene expression, genotyping or cytogenetic detection arrays to the launch of the GeneTitan® and GeneAtlas® platforms. Marty holds a PhD in Chemistry from the University of California at San Diego with a focus on physical organometallic chemistry.
Asim Siddiqui is Senior Vice President of Research and has a long history of leading research programs across academia and industry. In industry, the domains he has worked in include drug discovery (Chief Technology Officer at NuMedii), prenatal diagnostics (Vice President of Product Development at Natera) and genomics tools (Director of Bioinformatics at Life Technologies). In academia, he was Bioinformatics Group Leader at the BC Genome Sciences Centre and involved in a number of large-scale genomics projects including the cow genome and poplar genome. Asim has been an author over 40 peer-reviewed publications and holds a doctorate in Bioinformatics from Oxford University, and a degree in Physics from Cambridge University.